Join SightNation!

Become a citizen of our interactive community. Collaborate and network with your colleagues and trusted peers. Membership is free!

Connect with Colleagues

Link up with professionals all over the nation. Share your ideas, thoughts and opinions. Collaborate on difficult cases and offer your insights.

Communicate and Educate

Discuss new and important issues with your colleagues. Share your insights to help improve patient counseling. Post questions to your peers.

Learn and Advance

Take CE courses and rate courses for your peers. Find and apply for the newest jobs. Stay up-to-date on the latest eye care industry news.


Engage with SightNation citizens to help create real reform on issues affecting the industry. Start or join groups about the issues most important to you.

Create an account and receive access to the personalized box below.

Apply for Citizenship!

What’s Going On Across the Nation

New Blog Postings

SightNation News

Featured News

Study Uncovers the Brain’s Role in Glaucoma - 07.25.2014

Findings from a new study published in Translational Vision Science & Technology show the brain, not the eye, controls the cellular process that leads to glaucoma. More »

Featured News

U.S. Patent Covers Bromfenac Formulations in Durasite - 07.24.2014

The United States Patent and Trademark Office has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. More »

Featured News

FDA Clears Victus Femtosecond Laser Platform for Lens Fragmentation Procedure - 07.23.2014

Valeant Pharmaceutials International Inc.'s wholly owned subsidiary, Bausch + Lomb, has received 510(k) clearance from the FDA for the Victus Femtosecond Laser Platform for laser-assisted lens fragmen More »

Featured News

Zeiss Unveils Digital Lens to Meet the Needs of Mobile Device Users - 07.22.2014

For those born in the 1980s and 1990s, digital technology plays a part in almost every aspect of life—and consequently has a significant impact on vision. More »

Aerie Initiates Phase III Registration Trials of Glaucoma Drug - 07.21.2014

Dosing of the first patients enrolled in Aerie Pharmaceuticals Inc.'s Phase III registration clinical trials of Rhopressa commenced on July 11th. More »

Copyright © 2010 Jobson Medical Information LLC. All Rights Reserved.